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Open Reply to: ‘‘Sorafenib efﬁcacy for treatment of HCC recurrence
after liver transplantation is an open issue’’o the Editor:
We thank Dr. Mancuso et al. for their critical comments on our
ecent paper, in which we sought to demonstrate the efﬁcacy
nd the safety of sorafenib in a case-control study on trans-
lanted patients affected by HCC recurrence [1]. Rather than
eing diverted by academic abstractions, we would like to stick
o the data and take the opportunity of replying through the exp-
icitation of few points, some of them already expressed in our
riginal article. In brief:
(1) As any cohort study, our original report on consecutive
patients presenting with HCC recurrence after LT had some
limitations that had been extensively acknowledged both
in the text and in the accompanying editorial. However,
thanks to a solid statistical analysis, we fail to detect any
‘‘strong bias’’ (namely systematic errors) as those men-
tioned in the letter.
(2) We acknowledge the note of caution on sorafenib
safety, given the Authors’ [2] and another group’s [3] expe-
rience. However, we would like to underline that most of
the published studies including ours (Table 1) reported
adverse event and drug discontinuation rates that are in
line with that of RCTs in non-transplant patients: to be
noted, in the majority of these reports more than 50% of
patients received sorafenib in association with an mTOR
inhibitor. There is a clear heterogeneity in both safety
reports and survival outcomes that probably reﬂects the
heterogeneity of patients and of Centers’ policies. Overall,
the published data conﬁrms that sorafenib does not appear1. Published series including more than 5 patients that underwent sorafenib fo
hor (Journal, year) pts mTOR*
 R et al. (Oncology, 2010) 9 77.8%
n Dh et al. (Jpn J Clin Oncol 2010) 13 7.7%
mez Martin et al. (Liver Transpl 2012) 31 96.8%
iropulos GC et al. (Transplant Proc 2012) 14 100%
ufer K et al. (Transplant Int 2012) 13 69.2%
le A et al. (Transplant Proc 2012) 10 70%
inmann A et al. (Digest Liver Dis 2012) 11 81.8%
aglia C et al. (Eur J Gastroen Hepat 2013) 11 63.6%
sito C et al. (J Hepatol 2013) 15 46.7%
iffenberger J et al. (Langenbecks Arch Surg 2013) 8 25%
ntage of patients undergoing sorafenib + mTOR inhibitors.
ian, from starting of sorafenib.
e 5 AEs.
atients; mTOR, mammalian target of rapamycin inhibitors; AE, Adverse Event; TTP, T
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setting.
(3) Neither us nor the Editorial comment on our article [4]
recommended the use of sorafenib ‘‘to be added to the next
guidelines’’ on the management of HCC after transplant.
Given the preliminary nature of our investigation both the
article and the Editorial were very cautions in that respect,
although emphasizing that the signal of effectiveness
arising fromour comparative cohorts represents one impor-
tant step towards that may help in the design of guidelines
for the management of these patients. It has to be noted,
however, that up to now most of the treatments routinely
performed for HCC recurrence after LT (such as liver resec-
tion, TACE, etc.) and possibly considered in such guidelines
would lack the power of evidence grade 1–2 because of the
absence of randomized controlled trials (RCTs).
(4) In the present conditions the proposal of Dr. Mancuso et al.
of a multicenter RCT testing sorafenib vs. placebo in recur-
ring HCC after liver transplantation could be rated as
unethical, being sorafenib a compound with demonstrated
efﬁcacy in advanced HCC irrespective of different patient
characteristics and disease presentation [5]. We sincerely
think that studies like ours may give the rationale for trial
implementation and offer a ﬁeld practice perspective that
helps to unravel the clinical effectiveness and toxicity of
a drug when administered in real-life patients. In such per-
spective probably a single-arm prospective phase 3–4
study would better explore the safety of sorafenib and
the possible drug-to-drug interactions that are potentially
harmful in the transplant setting.r HCC recurrence after LT.
AE Discontinuation 
rate
TTP#
(mo)
OS#
(mo)
Grade 3-4 Grade 4-5
n.r. n.r. 0% n.r. n.r.
30.7% 0% 0% 2.9 5.4
n.r. 6.5%** 0% 6.8 19.3
n.r. n.r. 28.6% n.r. 12
92.3% n.r. 77% 7 19.4
n.r. 0% 33% 8 18
n.r. 0% 18% 4.1 20.1
n.r. 9.1%** 36% n.r. 5
n.r. 0% 6.7% 8.5 10.6
0% 0% 0% 4.5 9
ime To Progression; OS, Overall Survival; n.r., not reported.
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